(16-06-12) Lipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathy.

Das UN.
Source
School of Biotechnology, Jawaharlal Nehru Technological University, Kakinada, India; Bio-Science Research Centre, Gayatri Vidya Parishad College of Engineering, Visakhapatnam, India; UND Life Sciences, Shaker Heights, Ohio, USA.
Abstract
Diabetic macular edema and retinopathy are low-grade inflammatory conditions. Infusions of antitumor necrosis factor-? (anti-TNF-?) antibody and antivascular endothelial growth factor (anti-VEGF) antibody have been shown to be at least partly effective in the treatment of diabetic macular edema and proliferative diabetic retinopathy. Intravitreal therapy of diabetic macular edema by the anti-TNF-? antibody has been found to produce significant side effects and anti-VEGF therapy to be ineffective. Nevertheless, these studies have indicated that the suppression of TNF-? and other proinflammatory cytokines and VEGF could be of benefit in diabetic macular edema and retinopathy. The retina is rich in polyunsaturated fatty acids, especially in ?-3, and several studies have shown that polyunsaturated fattyacids prevent diabetic retinopathy. Lipoxins, resolvins, and protectins derived from various polyunsaturated fatty acidspossess anti-inflammatory actions and suppress the production of interleukin-6, and TNF-? and VEGF have antiangiogenic actions. In view of these evidences, I propose that lipoxins, resolvins, and protectins could be of significant benefit in the prevention and management of diabetic macular edema and retinopathy.

Source: Nutrition. 2012 Jun 5. [Epub ahead of print]

News

---

In evidenza

"L'informazione presente nel sito serve a migliorare, e non a sostituire, il rapporto medico-paziente."

Per coloro che hanno problemi di salute si consiglia di consultare sempre il proprio medico curante.